
This resource describes how state health departments and other public health organizations can partner with people with HIV and/or who use(d) drugs in programmatic and policy making processes and evaluation.
This resource describes how state health departments and other public health organizations can partner with people with HIV and/or who use(d) drugs in programmatic and policy making processes and evaluation.
This guide offers considerations for how state agency staff can develop and maintain an accessible, HIV and opioid use disorder (OUD) service inventory. This guide can be used by state agency HIV and OUD staff to:
Individuals who have HIV who also use drugs experience increased age-matched morbidity and mortality in comparison with those with HIV who do not use drugs.
This discussion guide is intended to elicit a comprehensive and concrete conversation about language, stigma, and discrimination as a means of strengthening care systems and ensuring that people who seek care for HIV and/or substance use disorders, including opioid use disorder, are treated with
This tool focuses on the role of stigma at the intersection of HIV and OUD systems, and introduces opportunities for intervention at the systems level.
The HIV and OUD Service and Funding Matrices Template supports state health departments in identifying opportunities for enhanced coordination between HIV and OUD funding and service provision.
This virtual session summary describes key takeaways from the August 2020 Let's Talk about SSPs as Essential Services conversation.
Developed as part of the Strengthening Systems of Care for People with HIV and Opioid Use Disorder project, this document contains brief descriptions of federal policy and systems changes due to coronavirus 2019 (COVID-19) that relate to the HIV and substance use systems of care, along w
This document provides an overview of the SAMHSA State Opioid Response (SOR) Funding Opportunity Announcement (FOA) TI-20-012 for fiscal year (FY) 2020, with a specific focus on incorporating strategies to address HIV/infectious diseases, harm reduction, and stimulant use.